Clinical trial NCT03477162 - References

Thoracic Neoplasm — Metformin Pharmacology in Human Cancers: A Proof of Principle Study

Citation(s)

•   Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR
  Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010 Jun;33(6):1304-8. doi: 10.2337/dc09-1791. Epub 2010 Mar 18.
•   Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL
  Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007 Sep 18;147(6):386-99. doi: 10.7326/0003-4819-147-6-200709180-00178. Epub 2007 Jul 16. Erratum In: Ann Intern Med. 2007 Dec 18;147(12):887.
•   Camacho L, Dasgupta A, Jiralerspong S
  Metformin in breast cancer - an evolving mystery. Breast Cancer Res. 2015 Jun 26;17(1):88. doi: 10.1186/s13058-015-0598-8.
•   Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, Kaplan J, Kalyan A, Altman JK, Platanias L, Giles F
  Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016 Jun 28;7(26):40767-40780. doi: 10.18632/oncotarget.8194.
•   Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H, Brosen K
  The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genomics. 2011 Dec;21(12):837-50. doi: 10.1097/FPC.0b013e32834c0010. Erratum In: Pharmacogenet Genomics. 2015 Jan;25(1):48-50.
•   Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S
  Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61. doi: 10.1158/1940-6207.CAPR-10-0157. Epub 2010 Oct 12.
•   DeFronzo RA, Goodman AM
  Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995 Aug 31;333(9):541-9. doi: 10.1056/NEJM199508313330902.
•   Diabetes Prevention Program Research Group
  Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012 Apr;35(4):731-7. doi: 10.2337/dc11-1299.
•   Dowling RJ, Lam S, Bassi C, Mouaaz S, Aman A, Kiyota T, Al-Awar R, Goodwin PJ, Stambolic V
  Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy. Cell Metab. 2016 Apr 12;23(4):567-8. doi: 10.1016/j.cmet.2016.03.006. No abstract available.
•   Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N
  Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007 Nov 15;67(22):10804-12. doi: 10.1158/0008-5472.CAN-07-2310.
•   Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
  UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):854-65. Erratum In: Lancet 1998 Nov 7;352(9139):1558.
•   El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X
  Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000 Jan 7;275(1):223-8. doi: 10.1074/jbc.275.1.223.
•   Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD
  Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005 Jun 4;330(7503):1304-5. doi: 10.1136/bmj.38415.708634.F7. Epub 2005 Apr 22. No abstract available.
•   Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D
  Diabetes and cancer: a consensus report. Diabetes Care. 2010 Jul;33(7):1674-85. doi: 10.2337/dc10-0666.
•   Glucophage XR product insert
  https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwjcrMLO8cPXAhWGZiYKHVe1DoMQFggrMAA&url=https%3A%2F%2Fpackageinserts.bms.com%2Fpi%2Fpi_glucophage.pdf&usg=AOvVaw2zAbyMgwlF7wxaXv60vtv3.
•   Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM
  Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011 Feb;50(2):81-98. doi: 10.2165/11534750-000000000-00000.
•   Gunton JE, Delhanty PJ, Takahashi S, Baxter RC
  Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab. 2003 Mar;88(3):1323-32. doi: 10.1210/jc.2002-021394. Erratum In: J Clin Endocrinol Metab. 2004 Jan;89(1):434.
•   Hurst RT, Lee RW
  Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med. 2003 Nov 18;139(10):824-34. doi: 10.7326/0003-4819-139-10-200311180-00010.
•   Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG
  Metformin: taking away the candy for cancer? Eur J Cancer. 2010 Sep;46(13):2369-80. doi: 10.1016/j.ejca.2010.06.012. Epub 2010 Jul 23.
•   Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM
  Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009 Jul 10;27(20):3297-302. doi: 10.1200/JCO.2009.19.6410. Epub 2009 Jun 1.
•   Kajbaf F, De Broe ME, Lalau JD
  Therapeutic Concentrations of Metformin: A Systematic Review. Clin Pharmacokinet. 2016 Apr;55(4):439-59. doi: 10.1007/s40262-015-0323-x.
•   Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL
  Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009 Aug;137(2):482-8. doi: 10.1053/j.gastro.2009.04.013. Epub 2009 Apr 16.
•   Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM
  New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009 Sep;32(9):1620-5. doi: 10.2337/dc08-2175. Epub 2009 Jun 29.
•   Lipska KJ, Bailey CJ, Inzucchi SE
  Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011 Jun;34(6):1431-7. doi: 10.2337/dc10-2361. No abstract available.
•   Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, Steele VE, Rao CV
  Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. Transl Oncol. 2013 Dec 1;6(6):649-59. doi: 10.1593/tlo.13556. eCollection 2013 Dec 1.
•   Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes
  Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan;32(1):193-203. doi: 10.2337/dc08-9025. Epub 2008 Oct 22.
•   Poloz Y, Stambolic V
  Obesity and cancer, a case for insulin signaling. Cell Death Dis. 2015 Dec 31;6(12):e2037. doi: 10.1038/cddis.2015.381.
•   Rena G, Pearson ER, Sakamoto K
  Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013 Sep;56(9):1898-906. doi: 10.1007/s00125-013-2991-0. Epub 2013 Jul 9.
•   Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM
  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007 May;117(5):1422-31. doi: 10.1172/JCI30558.
•   Timmins P, Donahue S, Meeker J, Marathe P
  Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet. 2005;44(7):721-9. doi: 10.2165/00003088-200544070-00004.
•   Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF
  Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981 Aug;12(2):235-46. doi: 10.1111/j.1365-2125.1981.tb01206.x.
•   Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F
  Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012 Mar;122(6):253-70. doi: 10.1042/CS20110386.
•   Wadamori N, Shinohara R, Ishihara Y
  Photoacoustic depth profiling of a skin model for non-invasive glucose measurement. Annu Int Conf IEEE Eng Med Biol Soc. 2008;2008:5644-7. doi: 10.1109/IEMBS.2008.4650494.
•   Witters LA
  The blooming of the French lilac. J Clin Invest. 2001 Oct;108(8):1105-7. doi: 10.1172/JCI14178. No abstract available.
•   Wright JL, Stanford JL
  Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control. 2009 Nov;20(9):1617-22. doi: 10.1007/s10552-009-9407-y. Epub 2009 Aug 4.
•   Xu H, Aldrich MC, Chen Q, Liu H, Peterson NB, Dai Q, Levy M, Shah A, Han X, Ruan X, Jiang M, Li Y, Julien JS, Warner J, Friedman C, Roden DM, Denny JC
  Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc. 2015 Jan;22(1):179-91. doi: 10.1136/amiajnl-2014-002649. Epub 2014 Jul 22.
•   Zakikhani M, Blouin MJ, Piura E, Pollak MN
  Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat. 2010 Aug;123(1):271-9. doi: 10.1007/s10549-010-0763-9. Epub 2010 Feb 5.
•   Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE
  Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001 Oct;108(8):1167-74. doi: 10.1172/JCI13505.

Metformin Pharmacology in Human Cancers

Details for clinical trial NCT03477162